Extrait

The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. This study will also provide another mechanism for reporting adverse events related to study drug safety.

Critère d'inclusion

• Pancreatic cancer,Colorectal Cancer,breastcancer,Lung Cancer, Non-Small Cell

Liens

• nct